Alimera Sciences, Inc., based in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, and is dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our product development portfolio being studied to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.
Alimera Sciences’ primary focus is on ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg. ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid therapy with a single injection.
ILUVIEN has received FDA approval in the United States for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
ILUVIEN has also been granted marketing authorizations in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom as “ILUVIEN® 190 micrograms intravitreal implant in applicator”, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.